ACP-HIP European Patent...News
Altachem Pharma Ltd.
Trading Symbol "AAF": Canadian Venture Exchange (CDNX)
News Release
ALTACHEM PHARMA’S ACP-HIP
EUROPEAN PATENT APPLICATION PUBLISHED
October 10, 2000
Warren Jackson, President and CEO of Altachem Pharma Ltd. is pleased to announce the receipt of "Notification" from the European Patent Office for our ACP-HIP patent application. The patent application has been published in the European Patent Bulletin under the publication number 1017722. Since this application is derived from an International Application after publication it is possible to obtain provisional protection in designated states.
ACP-HIP is a novel protein, which is extracted from pregnancy urine. Laboratory experiments indicate significant inhibitory action against Kaposi’s sarcoma cell growth as well as demonstrating anti-HIV activity. Furthermore, laboratory studies on human lymphocytes infected with the HIV virus and treated with ACP-HIP resulted in a significant inhibition of HIV expression.
After continued use of the current HAART (Highly Active Anti-Retroviral Therapy) patients are showing resistance to the drug, compounded with severe side effects. The prolonged administration of these HAART therapies in some cases necessitate discontinuation. Alternative therapies are urgently required. Natural Substances, including hormones, antihormones and their analogues, are increasingly being used as milder therapeutic agents, which target specific receptor-expressing cells.
Altachem Pharma hopes that results from further research of the ACP-HIP Technology may ultimately open the way to develop a new drug derived from a "natural" substance, which can be used for treatment of 33 million people currently living with HIV/AIDS worldwide.
Altachem Pharma Ltd. has also applied for patent protection in Canada, United States and China.
Altachem Pharma Ltd. is an Edmonton, Alberta based pharmaceutical company, which invests in, develops, manufactures and distributes pharmaceutical products according to GMP (Good Manufacturing Practice) guidelines and is certified compliant with internationally recognized quality system standards ISO 9002:1994, ISO 13488 and EN 46002.
For more information, please visit us on the WEB at www.altachempharma.com or contact Roger Andrews, Investor Relations at:
Phone: (780) 486-8331 ext. 331
Fax: (780) 448-1436
Toll Free Phone: (877) 502-5939
E-mail : Roger@altachempharma.com
This release may include ``forward-looking statement'' within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1034. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For informational purposes only, from sources deemed to be reliable.
"CDNX has neither approved or disapproved of the information contained herein." |
